Cargando…
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720354/ https://www.ncbi.nlm.nih.gov/pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211 |
_version_ | 1783619834813087744 |
---|---|
author | Brownlee, Wallace J |
author_facet | Brownlee, Wallace J |
author_sort | Brownlee, Wallace J |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7720354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77203542020-12-18 COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? Brownlee, Wallace J Mult Scler Case Report and Clinical Commentary SAGE Publications 2020-08-07 2020-09 /pmc/articles/PMC7720354/ /pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report and Clinical Commentary Brownlee, Wallace J COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
title | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
title_full | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
title_fullStr | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
title_full_unstemmed | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
title_short | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
title_sort | covid-19 and high-efficacy multiple sclerosis therapies: time for business as usual? |
topic | Case Report and Clinical Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720354/ https://www.ncbi.nlm.nih.gov/pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211 |
work_keys_str_mv | AT brownleewallacej covid19andhighefficacymultiplesclerosistherapiestimeforbusinessasusual |